Core Insights - The event on December 8, organized by People's Daily Health Client and supported by Yiling Pharmaceutical, marked the strategic partnership between Yiling Pharmaceutical and Alibaba Health to create a digital disease center for allergic rhinitis, integrating traditional Chinese medicine with modern digital health services [1][4] - The launch of the new product, Qifang Bitong Pian, was announced, which will be exclusively available on Alibaba Health [1][7] Group 1: Strategic Collaboration - Yiling Pharmaceutical and Alibaba Health signed a strategic cooperation agreement to develop a digital disease center for allergic rhinitis, aiming to provide authoritative education and precise services for patients [1][4] - The partnership seeks to bridge traditional Chinese medicine with modern digital health ecosystems, enhancing patient access to treatment [1][4] Group 2: Clinical Insights and Treatment Approaches - Allergic rhinitis incidence is rising, significantly affecting daily life, with environmental factors like vegetation changes and climate fluctuations contributing to its prevalence [2] - Traditional Chinese medicine (TCM) offers distinct advantages in treating allergic rhinitis, focusing on immune function regulation and long-term symptom relief through methods like Qi tonification and spleen strengthening [5][6] Group 3: Product Innovation - Qifang Bitong Pian, a class 1 innovative traditional Chinese medicine developed by Yiling Pharmaceutical, is set to be launched in January 2025 and has been included in the national medical insurance directory [6] - The product combines classic formulas and new ingredients, demonstrating efficacy in alleviating symptoms of allergic rhinitis and improving overall patient safety [6] Group 4: Policy and Market Dynamics - The integration of TCM into the medical insurance system is evolving, with recent policies supporting the inclusion of TCM innovations and emphasizing the need for evidence-based practices [8] - Yiling Pharmaceutical is committed to technological innovation and market transformation, having established over 60 compliant traditional Chinese medicine cultivation bases across the country [9]

Core Insights - The launch of the 5% minoxidil topical solution by Jissbon marks the brand's expansion into the hair health sector, previously known for its focus on sexual health products [1][4] - Hair loss is increasingly recognized as a public health issue, exacerbated by modern lifestyle factors such as stress and irregular routines, leading to a younger demographic experiencing hair loss [3][4] - The new minoxidil product aims to provide a low-sensitivity and refreshing user experience while ensuring stability and ease of storage, addressing key patient concerns regarding treatment effectiveness and safety [4][5] Product Details - The minoxidil solution utilizes a "golden concentration" of 5%, which is clinically validated for its efficacy in stimulating hair growth by improving local blood circulation around hair follicles [4] - The product is designed to withstand extreme temperatures, ensuring its usability in various conditions, which enhances consumer convenience [4] Market Strategy - Jissbon's entry into the hair health market is part of a broader strategy to diversify its product offerings, which now include male health medications, thereby creating a comprehensive portfolio in the sexual and health sectors [4][5] - The choice to launch on the Alibaba Health platform aligns with the company's strategy to leverage digital health platforms for efficient consumer engagement and to meet the demands of niche markets [4][5] Future Collaboration - Alibaba Health is positioned as a key partner for future product launches, with plans to deepen collaboration with Jissbon to develop new products that cater to consumer needs in the health sector [5]

Core Insights - The "Beijing +30" Business Leaders Summit, hosted by UN Women China, marked the 30th anniversary of the Beijing Declaration and Action Platform, focusing on women's empowerment and inclusive development [1][32] - The summit emphasized the importance of gender equality as a core driver for sustainable business development and called for more companies to join the Women's Empowerment Principles (WEPs) initiative [3][34] Group 1: Gender Equality and Economic Value - UN Women China highlighted that despite a 30% increase in women's labor participation and a decrease in poverty rates over the past 30 years, significant gender disparities remain, with women holding only 30% of management positions and facing a 20% wage gap [3][34] - Companies with gender-diverse boards show greater stock price stability and profitability potential compared to their peers, underscoring the economic value of gender equality [3][34] Group 2: Achievements and Challenges - China boasts a female labor participation rate of 62%, with women making up 53% of university graduates and 61.3% of business owners or leaders [5][36] - However, 314 million women are projected to face extreme poverty by 2030, indicating ongoing challenges in achieving gender equality [5][36] Group 3: Practical Approaches to Empower Women - The China Women's Development Foundation proposed three key integrations for supporting women's sustainable development: aligning national priorities with women's needs and corporate strategies, combining corporate strengths with execution systems, and investing in both material and human empowerment [7][38] - The private sector is encouraged to leverage innovation, financing, and employment to bridge gender gaps in the workplace [5][39] Group 4: Digital Empowerment and Future Trends - The upcoming UN Women flagship report will focus on gender equality practices in the digitalization process of Chinese enterprises, covering areas such as women's economic empowerment and health security [11][42] - The report will predict future trends related to AI and technology, aging populations, green transitions, and gender within the ESG framework, set to be released in 2026 [11][42] Group 5: Leadership and Collaboration - Discussions at the summit highlighted the need for modern leadership to combine strategic thinking with empathy, fostering team growth through interactive management [12][43] - Collaborative ecosystems involving government, businesses, NGOs, and women's groups are essential for advancing gender equality [8][39] Group 6: Commitment to Action - The summit concluded with a commitment ceremony for the Women's Empowerment Principles, where participants pledged to support workplace initiatives for women, including addressing menopause and advocating for equal retirement benefits [25][58] - The UN Women will continue to engage various sectors to integrate gender equality into corporate strategies and daily practices, aiming to turn the vision of the Beijing Declaration into lasting progress [29][60]

Group 1 - Alibaba Health and Yiling Pharmaceutical signed a strategic cooperation agreement on December 8 [1] - The collaboration focuses on the launch of Yiling's innovative traditional Chinese medicine, Qifang Nasal Tablets, and aims to enhance patient education and chronic disease management [1] - Both companies will jointly establish and operate a "Digital Disease Center for Allergic Rhinitis," creating a comprehensive health management loop covering disease awareness, medical science popularization, treatment recommendations, standardized medication guidance, and long-term follow-up [1]

里昂发布研报称，京东健康(06618) 与阿里健康(00241)今年第三季度业绩强劲，并鉴于以旧换新政策的 基数效应，认为这两间公司第四季度业绩指引较为保守，但他们对明年的药品销售增长及利润率扩张均 持正面展望。里昂预测两家公司明年收入将实现双位数增长，其中京东健康增速更快; 并将阿里健康目 标价从6.5港元下调至6港元，以反映第三方商品交易总额及营收增长预期放缓;而京东健康目标价则为 71港元;两间公司均维持"跑赢大市"评级。 里昂预计，上述两家公司原研药销售从医院内渠道转向医院外渠道，以及药企营销预算向线上转移的趋 势预计将持续数年。里昂又预计，两间公司下季度的营收年增率均在15%左右;并预计在原研药销售持 续增长的支撑下，京东健康2026财年营收将实现接近20%的同比增长，阿里健康2027财年营收将实现接 低十位数(low teens)的同比增长。然而，由于以旧换新基数较高，医疗器械销售可能会放缓，阿里健康 在营养品、第三方商品交易总额(GMV)和营收方面可能面临更大的压力;两家公司的长期调整后净利润 率约为13%。 ...

里昂发布研报称，京东健康（06618） 与阿里健康（00241）今年第三季度业绩强劲，并鉴于以旧换新政策的基数效应，认为这两间公司第四 季度业绩指引较为保守，但他们对明年的药品销售增长及利润率扩张均持正面展望。里昂预测两家公司 明年收入将实现双位数增长，其中京东健康增速更快； 并将阿里健康目标价从6.5港元下调至6港元，以反映第三方商品交易总额及营收增长预期放缓；而京东 健康目标价则为71港元；两间公司均维持"跑赢大市"评级。 里昂预计，上述两家公司原研药销售从医院内渠道转向医院外渠道，以及药企营销预算向线上转移的趋 势预计将持续数年。里昂又预计，两间公司下季度的营收年增率均在15%左右；并预计在原研药销售持 续增长的支撑下，京东健康2026财年营收将实现接近20%的同比增长，阿里健康2027财年营收将实现接 低十位数（low teens）的同比增长。然而，由于以旧换新基数较高，医疗器械销售可能会放缓，阿里健康在营养品、 第三方商品交易总额（GMV）和营收方面可能面临更大的压力；两家公司的长期调整后净利润率约为 13%。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 里昂发布研报称，京东健 ...

ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里健康信息技術有限公司 （於百慕達註冊成立之有限公司） 簽署6 日期 附註： 股東特別大會（或其任何續會）適用之代表委任表格 本人╱吾等1 地址為 乃阿里健康信息技術有限公司（「本公司」）股本中每股面值0.01港元之股份 股2 之登記持有人，茲委任股東特別大會主席或3 地址為 為本人╱吾等之代表，代表本人╱吾等出席本公司謹訂於2025年12月30日（星期二）下午二時正假座 中國杭州市余杭區五常街道文一西路969號菲住布渴酒店清風閣會議廳舉行之股東特別大會（「大會」） （或其任何續會），以考慮及酌情通過召開上述大會通告（「通告」）所載之決議案（不論有否經修訂或修 正），並於大會（或其任何續會）上代表本人╱吾等並以本人╱吾等之名義按下列指示就該等決議案 （不論有否修訂或修正）投票。如未有任何指示，則由本人╱吾等之代表酌情投票表決。 | | 普通決議案 | 贊成4 | 反對4 | | --- | --- | --- | --- | | 1. | 確認、批准及追認就本公司與杭州阿里媽媽軟件服務有限公司於 | | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里健康信息技術有限公司 （於百慕達註冊成立之有限公司） 普通決議案 「動議確認、批准及追認就本公司與杭州阿里媽媽軟件服務有限公司於2024年2月2 日訂立之2025年至2027年營銷推廣服務框架協議之截至2026年3月31日止年度之經 修訂年度上限人民3,600,000元及截至2027年3月31日止年度之經修訂年度上限人民 幣4,800,000元。」 承董事會命 阿里健康信息技術有限公司 首席執行官 沈滌凡 香港，2025年12月8日 附註： （股份代號：00241） 股東特別大會通告 茲通告阿里健康信息技術有限公司（「本公司」）謹訂於2025年12月30日（星期二）下午 二時正假座中國杭州市余杭區五常街道文一西路969號菲住布渴酒店清風閣會議廳 舉行股東特別大會（「股東特別大會」），以考慮及酌情通過下列普通決 ...

此 乃 要 件 請 即 處 理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢持牌證券交易商、股票經紀或其他註冊證券 商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已出售或轉讓所有名下之阿里健康信息技術有限公司股份，應立即將本通函及隨附之代表委任表格 送交買主或承讓人，或經手出售或轉讓之銀行、股票經紀或其他代理人，以便轉交買主或承讓人。 本通函僅供參考，並不構成收購、購買或認購阿里健康信息技術有限公司股份之邀請或要約。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本通函全部或任何部份內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。 ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里健康信息技術有限公司 （於百慕達註冊成立之有限公司） （股份代號：00241） 持續關連交易— 修訂2025年至2027年營銷推廣服務框架協議的 年度上限 及 股東特別大會通告 獨立董事委員會及獨立股東之 獨立財務顧問 ALTUS CAPITAL LIMITED ቺᑼၗԖज़Ϧљ ...

Group 1 - The core viewpoint is that Alibaba Health Technology has been a strategic investor in the company since May 2018 and continues to be one of the top ten shareholders as of September 30, 2025 [1] - The company collaborates with Alibaba Health and its associated platforms, including Alipay, Tmall, and Ele.me, to enhance its operational capabilities [1] - The company emphasizes that all operational information is disclosed through official announcements on the Giant Tide Information Network [1]